Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Breaking News

Fed's Powell says risk of higher inflation has increased

Regeneron says Roche successfully tested manufacture of COVID-19 drug used on Trump

CoronavirusNov 17, 2020 04:20PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
2/2 © Reuters. FILE PHOTO: George Yancopoulos, Regeneron Pharmaceuticals Co-Founder, President and Chief Scientific Officer, poses for a photograph on the company's Westchester campus in Tarrytown, New York 2/2

By Carl O'Donnell and Axel Threlfall

(Reuters) - Roche Holding AG (OTC:RHHVF) has completed early tests of its ability to produce large quantities of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)'s COVID-19 antibody treatment, putting it on track to begin manufacturing the drug once it is authorized by regulators, Regeneron's president said on Tuesday.

The experimental therapy was used to treat U.S. President Donald Trump in October. The companies aim to be able to make 2 million doses of the antibody cocktail next year, but are awaiting clearance from regulators.

Roche "has already started engineering runs at scale and (has) been successful," Regeneron President and Chief Scientific Officer George Yancopoulos said in an interview ahead of this week's Reuters Total Health conference.

A Roche spokesman said the Swiss drugmaker would be ready to begin producing the treatment in the first quarter of 2021.

Regeneron has had discussions with the U.S. Food and Drug Administration almost every day since it submitted its application for emergency use of the COVID-19 drug in October, and expects a final decision in the "very near future," Yancopoulos, a co-founder of the U.S. biotech company said.

Regeneron hopes to apply for full approval of the drug shortly afterwards, he said, echoing his comment during Regeneron's investor call earlier this month.

The company has a contract to provide 300,000 doses of the antibody therapy, called REGN-COV2, to the U.S. government and expects to be able to meet that commitment by as early as January. It has more than 50,000 doses currently stockpiled.

The 2 million doses Regeneron expects to be able to produce in partnership with Roche next year may not be enough to treat all the patients worldwide who could benefit from it, Yancopoulos said, based on the rate at which the virus is again spreading and sickening people globally.

He added that Regeneron is in talks with U.S. officials about providing more doses than it has already agreed to, but has not reached any conclusive agreement. Regeneron's current contract with the U.S. government priced 300,000 doses at $450 million.

Regeneron has been speaking regularly with U.S. President-elect Joe Biden's COVID-19 task force and has shown them a presentation on the antibody treatment, Yancopoulos said.

After Trump received the Regeneron treatment along with several other medicines during his bout with COVID-19, he touted it as a virtual "cure" for the illness, promising to make it free for Americans.

For more on Reuters Events Total Health click here:

Regeneron says Roche successfully tested manufacture of COVID-19 drug used on Trump

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email